Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3372689 · 6 trials · 2 indications
iADRS is a simple linear combination of scores from 13-item alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog13) and the Alzheimer's disease cooperative study-instrumental activities of daily living scale (ADCS-iADL). It is used to assess whether LY3372689 slows down the cognitive and functional decline associated with early symptomatic Alzheimer's Disease, compared to placebo. The iADRS score ranges from 0 to 144 with lower scores indicating worse performance and higher score better performance. Change from baseline was calculated using Bayesian disease progression model (DPM) adjusted for age at baseline, AChEI/Memantine use at baseline, pooled investigator. Data presented are posterior mean with 95% credible interval.
Percent OGA EO
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| 0.75 Milligram (mg) LY3372689 | EXPERIMENTAL | Double-blind treatment period: Participants received 0.75 mg LY3372689 administered orally once daily for up to 124 weeks. Post treatment follow up period: Participants who received 0.75 mg LY3372689 during the double-blind treatment period entered a post-treatment follow-up period for 4 weeks after last blinded treatment dose. No study intervention was administered during this period, and participants were followed for safety monitoring. Post treatment observational extension period: Participants who received 0.75 mg LY3372689 during the double-blind treatment period had the option to enter post-treatment observational extension period for approximately 9 months on average since last blinded treatment dose. No study intervention was administered during this period, and participants were followed for safety, other/exploratory efficacy and biomarker monitoring. |
| 3 mg LY3372689 | EXPERIMENTAL | Double-blind treatment period: Participants received 3 mg LY3372689 administered orally once daily for up to 124 weeks. Post treatment follow up period: Participants who received 3 mg LY3372689 during the double-blind treatment period entered a post-treatment follow-up period for 4 weeks after last blinded treatment dose. No study intervention was administered during this period, and participants were followed for safety monitoring. Post treatment observational extension period: Participants who received 3 mg LY3372689 during the double-blind treatment period had the option to enter post-treatment observational extension period for approximately 9 months on average since last blinded treatment dose. No study intervention was administered during this period, and participants were followed for safety, other/exploratory efficacy and biomarker monitoring. |
| Placebo | PLACEBO_COMPARATOR | Double-blind treatment period: Participants received placebo administered orally once daily for up to 124 weeks. Post treatment follow up period: Participants who received placebo during the double-blind treatment period entered a post-treatment follow-up period for 4 weeks after last blinded treatment dose. No study intervention was administered during this period, and participants were followed for safety monitoring. Post treatment observational extension period: Participants who received placebo during the double-blind treatment period had the option to enter post-treatment observational extension period for approximately 9 months on average since last blinded treatment dose. No study intervention was administered during this period, and participants were followed for safety, other/exploratory efficacy and biomarker monitoring. |
| [¹⁴C]-LY3372689 | EXPERIMENTAL | Single dose of \[¹⁴C\]-LY3372689 administered orally. |
| LY3372689 + [18F]LSN3316612 | EXPERIMENTAL | LY3372689 administered orally followed by \[18F\]LSN3316612 PET tracer administered intravenously (IV) approximately 24 hours later. |
| LY3372689 | EXPERIMENTAL | LY3372689 administered orally |
| Name | Type | Description |
|---|---|---|
| LY3372689 | DRUG | given orally |
| Placebo | DRUG | given orally |
| [¹⁴C]-LY3372689 | DRUG | Administered orally. |
| [18F]LSN3316612 | DIAGNOSTIC_TEST | Administered intravenously (IV). |
Inclusion Criteria: * Gradual and progressive change in memory function reported by participants or informants for ≥ 6 months * MMSE score of 22 to 30 (inclusive) at screening * CDR global score of 0.5 to 1.0 (inclusive), with a memory box score ≥0.5. * Meet 18F flortaucipir positron emission tomog...
Top 20 of 24 competitors
LY3372689 is an investigational small molecule being studied for Alzheimer's disease and in healthy participants. It is being developed by Eli Lilly and Company. The drug has completed Phase 2 testing in patients with Alzheimer's disease, and Phase 1 trials have been completed in healthy volunteers.
LY3372689 is a small molecule developed by Eli Lilly and Company. The specific molecular target of LY3372689 has not been disclosed in the available information. The drug is being studied for its safety, tolerability, and efficacy in participants with Alzheimer's disease.
LY3372689 is being developed by Eli Lilly and Company, which trades under the ticker symbol LLY. The company has completed Phase 1 and Phase 2 clinical trials for this investigational small molecule, which is being studied for Alzheimer's disease.
LY3372689 is in Phase 2 clinical development for Alzheimer's disease. The Phase 2 trial has been completed, and all five clinical trials for the drug have been completed. LY3372689 is investigational and has not been approved by the FDA.
LY3372689 has been studied in five completed clinical trials. These include Phase 1 safety studies in healthy participants (NCT03819270, NCT04106206, NCT05749848) and a Phase 2 efficacy study in Alzheimer's disease patients (NCT05063539). The Phase 2 trial enrolled 327 participants across the United States, Australia, Canada, Japan, and Poland.
LY3372689 is the primary name for this investigational drug developed by Eli Lilly and Company. No alternative names have been reported for this compound. The drug is being studied for Alzheimer's disease and has completed Phase 2 clinical trials.